Tempus AI's CEO Sold $6.6 Million in Stock the Day Before a Huge Rally. Here's What to Know
Key Points
The disposition of 133,000 shares was executed at a weighted average price of $49.61 per share, representing a total transaction value of about $6.6 million.
The activity was non-discretionary, performed solely to satisfy statutory tax withholding obligations associated with the vesting of restricted stock units.
Lefkofsky maintains a significant equity interest in the company.
- 10 stocks we like better than Tempus AI ›
Eric P. Lefkofsky, the chairman and CEO of Tempus AI, Inc. (NASDAQ:TEM), disposed of about 133,000 shares of Class A Common Stock on August 18, according to an SEC Form 4 filing
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $6.6 million |
| Shares sold (directly held) | 132,591 |
| Post-transaction shares (directly held) | 2,098,130 |
Transaction value based on SEC Form 4 weighted average sale price ($49.61); post-transaction value based on the August 18 market close ($49.36).
Key questions
- What was the structural nature of this share disposition?
The sale was non-discretionary, executed to cover tax obligations, and does not reflect the insider's view on the stock. This "sell to cover" mechanism is a standard arrangement used by the company to fund minimum statutory tax withholdings upon the vesting of equity awards. - What is the current scale of the CEO's equity exposure?
Lefkofsky continues to control a small but meaningful percentage of the company through his direct and indirect holdings. The insider also holds derivative securities. As of the August 19 market close, the stock was priced at $61.25, following a one-year total return of -37%.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $61.25 |
| Market Capitalization | $10.7 billion |
| Revenue (TTM) | $1.4 billion |
| Net Income (TTM) | -$254.4 million |
Company Snapshot
- Tempus AI operates a comprehensive healthcare technology platform that integrates clinical diagnostic capabilities with advanced analytics and multimodal data repositories, generating revenue through its Tempus platform and Hub clinical application for next-generation sequencing testing.
- The company operates a closed-loop, full-stack business model that establishes bi-directional integrations between clinician workflows and laboratory diagnostic services, enabling end-to-end solutions for healthcare providers and diagnostic testing.
- The company serves physicians, healthcare providers, and clinical laboratories seeking advanced diagnostic capabilities and data-driven clinical decision support, with a primary focus on oncology and precision medicine applications.
Tempus AI is a healthcare technology company based in Chicago with a $10.7 billion market capitalization and approximately 3,800 employees. The company has achieved TTM revenue of $1.4 billion while investing heavily in research and development, reflected in a TTM net loss of $254.4 million. The company's competitive advantage stems from its integrated platform architecture, which combines diagnostic capabilities, advanced analytics, and proprietary multimodal data repositories to deliver differentiated clinical decision support solutions.
What this transaction means for investors
Lefkofsky's sale itself is routine, a sell-to-cover on vested equity, but the timing is nevertheless interesting for Tempu stock. He disposed of about 133,000 shares on August 18, at a weighted average price of $49.61. The very next day, Tempus stock jumped 24% to $61.25, then another 9% the day after that, to $66.65, after Moderna and Merck reported Phase 3 melanoma trial results that validate the genomic sequencing technology behind Tempus's pending $1.5 billion Personalis acquisition. Of course, Lefkofsky sold the day before, not after, so there's no story here despite how it looks on a chart.
The business context makes clear why investors are excited regardless of one CEO's tax bill. Tempus posted its first GAAP profit in the second quarter, with revenue up 22% to $382.5 million and oncology volume growth of 31%. The company raised full-year guidance to roughly $1.6 billion, about 25% annual growth. Lefkofsky described the quarter plainly, saying "Q2 was another exceptional quarter for us." None of that was priced in before this week. For long-term investors, whether Tempus can turn a single trial readout into durable testing volume is the real question now, not a routine Form 4 filed a day too early to matter.
Should you buy stock in Tempus AI right now?
Before you buy stock in Tempus AI, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Tempus AI wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $432,189!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,330,956!*
Now, it’s worth noting Stock Advisor’s total average return is 967% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of August 22, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy.
Recommended Articles
